Clinical efficacy and safety of folic acid and vitamin B12 for the adjuvant treatment of schizophrenia: a systematic review and meta-analysis.

Eficacia clínica y seguridad del ácido fólico y la vitamina B12 como tratamiento adyuvante de la esquizofrenia: una revisión sistemática y metanálisis.

Palabras clave: ácido fólico, metanálisis, esquizofrenia, vitamina B 12

Resumen

En vista de los diferentes efectos del folato y la vitamina B 12b en el tratamiento adyuvante de la esquizofrenia (SCH), su eficacia y seguridad como terapia adyuvante para SCH fueron evaluadas sistemáticamente mediante la medicina basada en la evidencia. La recuperación de publicaciones se realizó en base a bases de datos autorizadas como Cochrane Library, PubMed y Web of Science para la selección de ensayos controlados aleatorios (ECA). Después de la evaluación de la calidad y la extracción de datos de los estudios incluidos, los ECA elegibles se revisaron sistemáticamente mediante el software Review Manager 5.2. En total, se incluyeron 14 ECA. Los resultados del metanálisis revelaron que, como terapia adyuvante para la SCH, la vitamina B12 difería significativamente del folato en términos de tasa de alivio de la ansiedad [odds ratio (OR) = 1,28, intervalo de confianza (IC) del 95% (1,02, 1,61), p=0,03, I2 =0%, Z=2,13], pero no hubo diferencias significativas en la tasa de incidencia de manía [OR=1,13, IC 95% (0,78,1,65), p=0,65, I2=36%, Z= 0,65], eficacia total [OR=1,06, IC 95% (0,72, 1,56), p=0,77, I2=0%, Z=0,30] y tasa de incidencia de reacciones adversas [OR=1,15, IC 95% (0,88, 1,49 ), p=0,31, I2=0%, Z=1,03]. Aunque el folato y la vitamina B 12 no presentan diferencias significativas en el tratamiento adyuvante de la SCH, la vitamina B12 ejerce notablemente menos efectos secundarios que los fármacos de folato y tiene una importancia orientativa para la medicación adyuvante clínica de la SCH.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Kai Niu, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Department of Psychiatry, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Ximin Zhao, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Medical Record Statistics Office, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Ying Wei, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Medical Record Statistics Office, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Yuefeng Wang, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Department of Psychiatry, Zhoushan Second People’s Hospital, Zhoushan, Zhejiang Province, China.

Citas

Ma F, Zhou X, Li Q, Zhao J, Song A, An P, Du Y, Xu W, Huang G. Effects of folic acid and vitamin B12, alone and in combination on cognitive function and inflammatory factors in the elderly with mild cognitive impairment: a single-blind experimental design. Curr Alzheimer Res 2019; 16(7): 622-632. https://doi.org/10.2174/156720 5016666190725144629.

van de Leemput J, Hess JL, Glatt SJ, Tsuang MT. Genetics of schizophrenia: historical insights and prevailing evidence. Adv Genet 2016; 96: 99-141. https://doi. org/10.1016/bs.adgen.2016.08.001.

Satapathy S, Bandyopadhyay D, Patro BK, Khan S, Naik S. Folic acid and vitamin B12 supplementation in subjects with type 2 diabetes mellitus: A multiarm randomi­zed controlled clinical trial. Complement Ther Med 2020; 53: 102526. https://doi.org/10.1016/j.ctim.2020.102526.

Richetto J, Meyer U. Epigenetic modifi­cations in schizophrenia and related di­sorders: molecular scars of environmen­tal exposures and source of phenotypic variability. Biol Psychiatry 2021; 89(3): 215-226. https://doi.org/10.1016/j.biop­sych.2020.03.008.

Almeida OP, Ford AH, Flicker L. Syste­matic review and meta-analysis of rando­mized placebo-controlled trials of folate and vitamin B12 for depression. Int Psycho­geriatr 2015; 27(5): 727-737. https://doi. org/10.1017/S1041610215000046.

Bortolon C, Macgregor A, Capdevie­lle D, Raffard S. Apathy in schizophre­nia: A review of neuropsychological and neuroanatomical studies. Neuropsycho­logia 2018; 118(Pt B): 22-33. https:// doi.org/10.1016/j.neuropsychologia. 2017.09.033.

Guéant JL, Guéant-Rodriguez RM, Al­pers DH. Vitamin B12 absorption and malabsorption. Vitam Horm 2022; 119: 241-274. https://doi.org/10.1016/bs.vh. 2022.01.016.

Izawa J, Asai T, Imamizu H. Computatio­nal motor control as a window to unders­tanding schizophrenia. Neurosci Res 2016; 104: 44-51. https://doi.org/10.1016/j.neu­res.2015.11.004.

Shen L, Ji HF. Associations between ho­mocysteine, folic acid, vitamin B12 and Alzheimer’s Disease: iInsights from meta­analyses. J Alzheimers Dis 2015; 46(3): 777-790. https://doi.org/10.3233/JAD­150140.

Hosák L, Silhan P, Hosáková J. Genome­wide association studies in schizophrenia, and potential etiological and functio­nal implications of their results. Acta Medica 2012; 55(1): 3-11. https://doi. org/10.14712/18059694.2015.67.

Hsu YC, Ye Z, Dai L, Jing Y, Tsui KL, Yip PS, Li W, Zhang Q. Understanding MMPI-2 response structure between schi­zophrenia and healthy individuals. Front Psychiatry 2022; 13: 918999. https://doi. org/10.3389/fpsyt.2022.918999.

Yazici AB, Akcay Ciner O, Yazici E, Ci­lli AS, Dogan B, Erol A. Comparison of vitamin B12, vitamin D and folic acid blood levels in patients with schizophre­nia, drug addiction and controls. J Clin Neurosci 2019; 65: 11-16. https://doi. org/10.1016/j.jocn.2019.04.031.

Yazici E, Mutu Pek T, Guzel D, Yazici AB, Akcay Ciner O, Erol A. Klotho, vitamin D and homocysteine levels during acute episode and remission periods in schizo­phrenia patients. Nord J Psychiatry 2019; 73(3): 178-184. https://doi.org/10.1080/08039488.2019.1582697.

Altun H, Sahin N, Belge Kurutas E, Gün­gör O. Homocysteine, pyridoxine, fola­te and vitamin B12 levels in children with attention deficit hyperactivity disorder. Psychiatr Danub 2018; 30(3): 310-316. https://doi.org/10.24869/psyd.2018.310.

Hope S, Naerland T, Høiland AL, Torske T, Malt E, Abrahamsen T, Nerhus M, Weder­vang-Resell K, Lonning V, Johannessen J, Steen NE, Agartz I, Stenberg N, Hun­dhausen T, Mørkrid L, Andreassen OA. Higher vitamin B12 levels in neurodevelop­mental disorders than in healthy controls and schizophrenia: A comparison among participants between 2 and 53 years. FA­SEB J 2020; 34(6): 8114-8124. https://doi.org/10.1096/fj.201900855RRR.

Allott K, McGorry PD, Yuen HP, Firth J, Proffitt TM, Berger G, Maruff P, O’Regan MK, Papas A, Stephens TCB, O’Donnell CP. The vitamins in psychosis study: a randomized, double-blind, placebo-con­trolled trial of the effects of vitamins B12, B6, and folic acid on symptoms and neu­rocognition in first-episode psychosis. Biol Psychiatry 2019; 86(1): 35-44. https://doi. org/10.1016/j.biopsych.2018.12.018.

Topal Z, Tufan AE, Karadag M, Gokcen C, Akkaya C, Sarp AS, Bahsi I, KilincM. Evaluation of peripheral inflammatory markers, serum B12, folate, ferritin levels and clinical correlations in children with autism spectrum disorder (ASD) and atention deficit hyperactivity disorder (ADHD). Nord J Psychiatry 2022; 76(2): 150-157. https://doi.org/10.1080/080394 88.2021.1946712.

Ramaekers VT, Thöny B, Sequeira JM, Ansseau M, Philippe P, Boemer F, Bours V, Quadros EV. Folinic acid treatment for schizophrenia associated with folate receptor autoantibodies. Mol Genet Me­tab 2014; 113(4): 307-314. https://doi. org/10.1016/j.ymgme.2014.10.002.

Chen CH, Chen PY, Chen CY, Chiu CC, Lu ML, Huang MC, Lin YK, Chen YH. Associa­tions of genetic variants of methylenetetra­hydrofolate reductase and serum folate le­vels with metabolic parameters in patients with schizophrenia. Int J Environ Res Pu­blic Health 2021; 18(21): 11333. https:// doi.org/10.3390/ijerph182111333.

Misiak B, Frydecka D, Kiejna A. Effects of second-generation antipsychotics on se­lected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. Eur J Clin Pharmacol 2014; 70(12): 1433-1441. https://doi.org/10.1007/s00228-014­1762-2.

Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S. Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cor­tisol in never-medicated schizophrenia pa­tients: implications for altered one-carbon metabolism. Psychiatry Res 2010; 175(1­2): 47-53. https://doi.org/10.1016/j.psy chres.2009.01.013.

Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Sil­verstein NJ, Smoller JW, Hill M, Goff DC. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013; 70(5): 481-489. https://doi.org/10.1001/ jamapsychiatry.2013.900.

Saedisomeolia A, Djalali M, Moghadam AM, Ramezankhani O, Najmi L. Folate and vitamin B12 status in schizophrenic patients. J Res Med Sci 2011; 16 Suppl 1: S437-S441. PMID: 22247731.

Misiak B, Laczmanski L, Sloka NK, Sz­mida E, Piotrowski P, Loska O, Slezak R, Kiejna A, Frydecka D. Metabolic dys­regulation in first-episode schizophrenia patients with respect to genetic variation in one-carbon metabolism. Psychiatry Res 2016; 238: 60-67. https://doi.org/ 10.1016/j.psychres.2016.01.077.

Misiak B, Kiejna A, Frydecka D. The his­tory of childhood trauma is associated with lipid disturbances and blood pressu­re in adult first-episode schizophrenia pa­tients. Gen Hosp Psychiatry 2015; 37(4): 365-367. https://doi.org/10.1016/j.gen­hosppsych.2015.03.017.

Gadgil M, Joshi K, Pandit A, Otiv S, Joshi R, Brenna JT, Patwardhan B. Imbalance of folic acid and vitamin B12 is associa­ted with birth outcome: An Indian preg­nant women study. Eur J Clin Nutr 2014; 68(6): 726-729. https://doi.org/10.1038/ ejcn.2013.289.

Möller HJ. Is schizophrenia still one entity with similar symptomatic patterns, neuro­biological characteristics, and treatment perspectives? Eur Arch Psychiatry Clin Neurosci 2018; 268(6): 525-527. https:// doi.org/10.1007/s00406-018-0926-y.

Lawrie SM, Hall J, McIntosh AM, Cun­ningham-Owens DG, Johnstone EC. Neu­roimaging and molecular genetics of schi­zophrenia: pathophysiological advances and therapeutic potential. Br J Pharmacol 2008; 153 Suppl 1: S120-S124. https:// doi.org/10.1038/sj.bjp.0707655.

Rothenberg SP. Application of competitive ligand binding for the radioassay of vitamin and folic acid. Metabolism 1973; 22(8):B12 1075-1082. https://doi.org10.1016/0026­0495(73)90226-6./

Roberts MT, Shokraneh F, Sun Y, Groom M, Adams CE. Classification of psychothe­rapy interventions for people with schizo­phrenia: development of the Nottingham Classification of Psychotherapies. Evid Based Ment Health 2021; 24(2): 62-69. https://doi.org/10.1136/ebmental-2020­300151.

Lin CH, Yang S, Huang YJ, Lane HY. Poly­morphism in the LASP1 gene promoter re­gion alters cognitive functions of patients with schizophrenia. Sci Rep 2019; 9(1): 18840. https://doi.org/10.1038/s41598­019-55414-1.

Dang S, Yan H, Zeng L, Wang Q, Li Q, Xiao S, Fan X. The status of vitamin B12 and folate among Chinese women: a po­pulation-based cross-sectional study in northwest China. PLoS One 2014; 9(11): e112586. https://doi.org/10.1371/jour­nal.pone.0112586.

Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cog­nition and dementia. Cochrane Database Syst Rev 2003; (4): CD004514. https:// doi.org/10.1002/14651858.CD004514

Pomarol-Clotet E, Salvador R, Murray G, Tandon S, McKenna PJ. Are there va-lid subtypes of schizophrenia? A grade of membership analysis. Psychopatho­logy 2010; 43(1): 53-62. https://doi. org/10.1159/000260044.

Satoskar RS, Kulkarni BS, Mehta BM. Serum vitamin B12 and folic acid (P.G.A.) levels in hypoproteinaemia and marasmus in Indian children. Arch Dis Child 1962; 37(191): 9-16. https://doi.org/10.1136/ adc.37.191.9.

McIntosh AM, Gow A, Luciano M, Da­vies G, Liewald DC, Harris SE, Corley J, Hall J, Starr JM, Porteous DJ, Tenesa A, Visscher PM, Deary IJ. Polygenic risk for schizophrenia is associated with cog­nitive change between childhood and old age. Biol Psychiatry 2013; 73(10): 938­943. https://doi.org/10.1016/j.biopsych. 2013.01.011.

Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, Lorenzl S, Linnebank M. Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: re­view and treatment recommendations. Ex­pert Rev Neurother 2009; 9(9): 1393-1412. https://doi.org/10.1586/ern.0 9.75.

Cocchi E, Drago A, Serretti A. Hippo­campal pruning as a new theory of schi­zophrenia Etiopathogenesis. Mol Neuro­biol 2016; 53(3): 2065-2081. https://doi. org/10.1007/s12035-015-9174-6.

Girdwood RH. Abnormalities of vitamin B12 and folic acid metabolism--their in­fluence on the nervous system. Proc Nutr Soc 1968; 27(1): 101-107. https://doi. org/10.1079/pns19680021.

Yang QX, Wang YX, Li FC, Zhang S, Luo YC, Li Y, Tang J, Li B, Chen YZ, Xue WW, Zhu F. Identification of the gene signatu­re reflecting schizophrenia’s etiology by constructing artificial intelligence-based method of enhanced reproducibility. CNS Neurosci Ther 2019; 25(9): 1054-1063. https://doi.org/10.1111/cns.13196.

Williams JN. Some metabolic interrela­tionships of folic acid, vitamin B12, and as­corbic acid. Am J Clin Nutr 1955; 3(1): 20­29. https://doi.org/10.1093/ajcn/3.1.20.

Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Sil­verstein NJ, Smoller JW, Hill M, Goff DC. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013; 70(5): 481-489. https://doi.org/10.1001/ jamapsychiatry.2013.900.

Publicado
2023-08-25
Cómo citar
Niu, K., Zhao, X., Wei, Y., & Wang, Y. (2023). Clinical efficacy and safety of folic acid and vitamin B12 for the adjuvant treatment of schizophrenia: a systematic review and meta-analysis.: Eficacia clínica y seguridad del ácido fólico y la vitamina B12 como tratamiento adyuvante de la esquizofrenia: una revisión sistemática y metanálisis. Investigación Clínica, 64(3), 424-436. https://doi.org/10.54817/IC.v64n3a12